MX2017004046A - Derivados de acido boronico. - Google Patents

Derivados de acido boronico.

Info

Publication number
MX2017004046A
MX2017004046A MX2017004046A MX2017004046A MX2017004046A MX 2017004046 A MX2017004046 A MX 2017004046A MX 2017004046 A MX2017004046 A MX 2017004046A MX 2017004046 A MX2017004046 A MX 2017004046A MX 2017004046 A MX2017004046 A MX 2017004046A
Authority
MX
Mexico
Prior art keywords
acid derivatives
boronic acid
abnomality
lmp7
inhibitors
Prior art date
Application number
MX2017004046A
Other languages
English (en)
Other versions
MX370336B (es
Inventor
Klein Markus
Schadt Oliver
Haselmayer Philipp
Busch Michael
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2017004046A publication Critical patent/MX2017004046A/es
Publication of MX370336B publication Critical patent/MX370336B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Abstract

Los compuestos de la fórmula (I) son inhibidores de LMP7 y se pueden emplear, inter alia, para el tratamiento de una anormalidad de trastorno autoinmunitario o malignidades hematológicas. (ver Fórmula).
MX2017004046A 2014-10-01 2015-10-01 Derivados de acido boronico. MX370336B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14003392 2014-10-01
PCT/EP2015/002008 WO2016050359A1 (en) 2014-10-01 2015-10-01 Boronic acid derivatives

Publications (2)

Publication Number Publication Date
MX2017004046A true MX2017004046A (es) 2017-06-19
MX370336B MX370336B (es) 2019-12-10

Family

ID=51690789

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004046A MX370336B (es) 2014-10-01 2015-10-01 Derivados de acido boronico.

Country Status (14)

Country Link
US (1) US10294246B2 (es)
EP (1) EP3201207B1 (es)
JP (1) JP6835711B2 (es)
KR (1) KR102450583B1 (es)
CN (1) CN107001390B (es)
AU (1) AU2015327346B2 (es)
BR (1) BR112017006420A2 (es)
CA (1) CA2963205A1 (es)
ES (1) ES2873000T3 (es)
IL (1) IL251301B (es)
MX (1) MX370336B (es)
RU (1) RU2017115188A (es)
SG (1) SG11201702623TA (es)
WO (1) WO2016050359A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016050356A1 (en) 2014-10-01 2016-04-07 Merck Patent Gmbh Boronic acid derivatives
BR112017006622A2 (pt) 2014-10-01 2018-07-03 Merck Patent Gmbh derivados de ácido borônico
WO2016050355A1 (en) 2014-10-01 2016-04-07 Merck Patent Gmbh Boronic acid derivatives
AU2018321118B2 (en) * 2017-08-24 2023-06-15 Merck Patent Gmbh Boronic acid derivatives
CN112469480A (zh) * 2018-07-26 2021-03-09 默克专利股份公司 硼酸衍生物
CN113135943A (zh) * 2020-01-19 2021-07-20 首药控股(北京)有限公司 硼酸衍生物
CN113135944A (zh) * 2020-01-19 2021-07-20 首药控股(北京)有限公司 硼酸衍生物
WO2022187362A1 (en) * 2021-03-02 2022-09-09 Case Western Reserve University Β-lactamase inhibitors and uses thereof
CA3227452A1 (en) 2021-07-29 2023-02-02 Merck Patent Gmbh Novel crystalline forms of [(1r)-2-(1-benzofuran-3-yl)-1-{[(1s,2r,4r)-7- oxabicyclo[2.2.1]heptan-2-yl]formamido}ethyl]boronic acid, adducts thereof, and processes to obtain
WO2023061445A1 (zh) * 2021-10-14 2023-04-20 首药控股(北京)股份有限公司 硼酸衍生物
WO2023232830A1 (en) 2022-06-02 2023-12-07 Merck Patent Gmbh Boronic acid adducts

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111175A0 (en) * 1993-10-07 1994-12-29 Du Pont Merck Pharma Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them
EP1196436A2 (en) * 1999-07-07 2002-04-17 Bristol-Myers Squibb Pharma Company Peptide boronic acid inhibitors of hepatitis c virus protease
US7271186B1 (en) * 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
AU2008321443A1 (en) * 2007-11-13 2009-05-22 Novartis Ag Beta-lactamase inhibitors
AR075090A1 (es) * 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
WO2013092979A1 (en) * 2011-12-22 2013-06-27 Ares Trading S.A. Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
WO2016050356A1 (en) 2014-10-01 2016-04-07 Merck Patent Gmbh Boronic acid derivatives
BR112017006622A2 (pt) 2014-10-01 2018-07-03 Merck Patent Gmbh derivados de ácido borônico
WO2016050355A1 (en) 2014-10-01 2016-04-07 Merck Patent Gmbh Boronic acid derivatives

Also Published As

Publication number Publication date
US10294246B2 (en) 2019-05-21
AU2015327346B2 (en) 2019-12-05
WO2016050359A1 (en) 2016-04-07
CA2963205A1 (en) 2016-04-07
CN107001390A (zh) 2017-08-01
KR20170062517A (ko) 2017-06-07
IL251301A0 (en) 2017-05-29
JP2017536335A (ja) 2017-12-07
EP3201207A1 (en) 2017-08-09
BR112017006420A2 (pt) 2017-12-19
CN107001390B (zh) 2020-11-27
KR102450583B1 (ko) 2022-10-04
ES2873000T3 (es) 2021-11-03
AU2015327346A1 (en) 2017-05-18
RU2017115188A (ru) 2018-11-06
MX370336B (es) 2019-12-10
RU2017115188A3 (es) 2019-03-29
US20180105539A1 (en) 2018-04-19
EP3201207B1 (en) 2021-02-24
IL251301B (en) 2022-02-01
JP6835711B2 (ja) 2021-02-24
SG11201702623TA (en) 2017-04-27

Similar Documents

Publication Publication Date Title
PH12017500293A1 (en) Boronic acid derivatives
MX2017004043A (es) Derivados de acido boronico.
MX2017004037A (es) Derivados de acido boronico.
MX2017004046A (es) Derivados de acido boronico.
IL259787A (en) Mutant isocitrate dehydrogenase 1 (idh1) suppressor for the treatment of malignancies
PH12017500509A1 (en) Benzyl substituted indazoles as bub1 inhibitors
NZ724691A (en) Quinoline derivatives as smo inhibitors
MX2016012829A (es) Inhibidores de biaril cinasa.
TW201613886A (en) 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
PH12017500745A1 (en) Bromodomain inhibitors
NZ730603A (en) Mk2 inhibitors and uses thereof
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
AU2015299431B2 (en) Pyrrolidinone derivatives as metAP-2 inhibitors
PH12017501071A1 (en) Dihydropyrimidin-2-one compounds and medical use thereof
MX2015009818A (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerosis multiple.
MA39824A (fr) Composés azole amido-substitués
MX2016002924A (es) Inhibidores de cinasa a base de eter arilico.
MX2016009355A (es) Inhibidores de aril lactama cinasa.
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EA201791099A1 (ru) Хинолин карбоксамиды для применения в лечении лейкоза
TN2016000208A1 (en) Novel compound for treatment of severe hypoglycemia.
PH12016501184A1 (en) Novel compound for treatment of severe hypoglycemia
TN2016000181A1 (en) Novel compound for treatment of severe hypoglycemia.
TW201613928A (en) Vinyl compounds as inhibitors for FGFR and VEGFR

Legal Events

Date Code Title Description
FG Grant or registration